ATRIX LABORATORIES INC
Form 8-K
February 05, 2002

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

January 24, 2002
(Date of earliest event reported)

ATRIX LABORATORIES, INC.
(Exact name of Registrant as specified in its charter)

Delaware	0-18231	84-1043826
(State or Other Jurisdiction of Incorporation)	(Commission File No.)	(IRS Employer Identification No.)

2579 Midpoint Drive, Fort Collins, Colorado 80525
(Address of principal executive offices, including zip code)

(970) 482-5868
(Registrant's telephone number, including area code)

Item 5. Other Events.

On January 24, 2002, Atrix Laboratories, Inc. announced that it had received approval from the U.S. Food and Drug Administration for Eligard(TM) 7.5mg (formerly Leuprogel One-Month Depot), leuprolide acetate for subcutaneous injection for treatment of advanced prostate cancer.

For more information, see the press release attached hereto as Exhibit 99.1.

Item 7. Exhibits.

99.1 Press Release dated January 24, 2002

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ATRIX LABORATORIES, INC.

By: /s/ Brian G. Richmond

Brian G. Richmond
Chief Financial Officer

Date: February 4, 2002

EXHIBIT INDEX

EXHIBIT	DESCRIPTION
99.1	Press Release dated January 24, 2002